Last reviewed · How we verify
NCT05450120
Rehabilitation of Critically Ill Patients With SARS-CoV-2 Variants in ICU With Limited Resources
NA trial testing Functional Rehabilitation in COVID-19 Acute Respiratory Distress Syndrome in 88 participants. Status unknown.
1 October 2020
Quick facts
| Lead sponsor | Universidade Federal de Sao Carlos |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 88 |
| Start date | 1 May 2020 |
| Primary completion | 1 October 2020 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Functional Rehabilitation
- Neuromuscular Electrical Stimulation
Conditions studied
- COVID-19 Acute Respiratory Distress Syndrome — all drugs for COVID-19 Acute Respiratory Distress Syndrome →
Sponsor
Universidade Federal de Sao Carlos
Who can join
18 and older, any sex, with COVID-19 Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute rehabilitation in critically ill patients can improve post-intensive care unit (post-ICU) physical function. Scientific evidence has considered neuromuscular electrical stimulation (NMES) as a promising approach for the early rehabilitation of patients during and/or after ICU. Neuromuscular electrostimulation can be an alternative form of muscle exercise that helps to gain strength in critically ill patients with COVID -19, due to the severe weakness that patients experience due to longer MV, analgesia and NMB duration. Thus, the general objective of evaluating the effects of an early rehabilitation protocol on the strength and functionality of patients affected by SARS-CoV-2 variants and specifically compare the effectiveness of NMES associated with the functional rehabilitation protocol(FR). Also, describe demographics, clinical status, ICU therapies, mortality estimates and Hospital outcomes, of every patients admitted in ICU during the observation periods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05450120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Acute Respiratory Distress Syndrome
Currently open trials in the same condition.
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT04964115 — Post Acute Sequelae of COVID-19 · active not recruiting
- NCT05164744 — Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors · recruiting
- NCT04896853 — Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® · Phase 1 · active not recruiting
Other Universidade Federal de Sao Carlos trials
Trials by the same sponsor.
- NCT06259344 — Pain Science Education Administered in Full or Fractioned Dosage Modes for Temporomandibular Disorders · NA · not yet recruiting
- NCT06678698 — Acute Effect of Photobiomodulation in Individuals with Hypertension · NA · recruiting
- NCT06866522 — Light Reflection on Human Skin in Whole-Body Photobiomodulation Therapy · NA · recruiting
- NCT05996991 — The Impact of Positive, Neutral and Negative Expectation Speech on Manipulative Therapy Effects · NA · unknown
- NCT05989815 — Effect of Whole-body Photobiomodulation on Muscular Performance Enhancement. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05450120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidade Federal de Sao Carlos
- Last refreshed: 8 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05450120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing